2631-2581
2631-2581
S2631-25812021000100115
10.46997/revecuatneurol30100115
España
España
España
00
07
2021
00
07
2021
30
1
115
124
[
2019
76
2
2
113-7
]
[
2005
47
8
8
571-6
]
[
2013
55
6
6
509-19
]
[
2017
5
21
]
[
2003
49
1
1
7-12
]
[
2017
4
4
4
]
[
2019
19
1
1
111
]
[
2015
57
12
12
1105-18
]
[
2004
11
1
1
47-57
]
[
2019
65
166-71
]
[
2016
58
S5
S5
47
]
[
2009
51
6
6
487-90
]
[
2004
2
2
CD003466
]
[
2017
59
4
4
355-60
]
[
2008
50
10
10
784-9
]
[
2014
]
[
2014
24
4
4
345-51
]
[
2007
45
6
6
365-75
]
[
2020
9
^sSuppl 1
^sSuppl 1
Suppl 1
S125-35
]
[
2017
51
3
3
240-55
]
[
2019
21
4
4
261-81
]
[
2016
20
6
6
810-5.
]
[
2014
40
61
]
[
2015
7
11
11
9400-15
]
[
2011
128
2
2
e299-307
]
[
2017
65
2
2
242-64
]
[
2020
]
[
2008
50
8
8
625-30
]
[
2010
39
4
4
216-24
]
[
2003
88
1
1
75-8.
]
[
2016
12
4
4
e97-e103
]
[
2020
245-54
]
[
2009
51
10
10
773-8.
]
[
2012
56
4
4
306-12
]
[
2020
18
1
1
20
]
[
2016
58
9
9
918-23
]
[
National Guideline Alliance (UK)
2017
]
[
2014
]
[
2018
3
1
1
137-46
]
[
2014
]
[
2020
]
[
2014
]
[
2016
79
2
2
69-73
]
[
2011
109
5
5
447-52
]
[
2014
7
2
2
109-18
]
[
2016
92
6
6
549-58
]
[
1988
3
2
2
73-8
]
[
2010
52
2
2
e23-8
]
[
2012
11
CD008624
]
[
2016
30
63-71
]
[
2014
]
[
2016
105
6
6
665-70
]
[
SPARCLE group
2013
98
6
6
434-40
]
[
2017
139
6
6
e20171002
]
[
2017
59
8
8
858-63
]
[
2006
16
3
3
258-65
]
[
OMS
2020
]
[
2015
23
3
3
242-51
]